IP Library › Granted Patent US 12,674,139
Granted Patent B2
US 12,674,139 · App. 17/641,699 · Granted Jul 7, 2026

Serum-free medium not containing albumin and suited for culturing human hematopoietic stem cells, and albumin-free culturing method

Inventors: Satoshi Yamazaki (Tokyo, JP); Motoo Watanabe (Tokyo, JP); Masatoshi Sakurai (Tokyo, JP); Hiromitsu Nakauchi (Tokyo, JP)
Assignee: The University of Tokyo
C12N5/0647C12N2500/50C12N2500/90C12N2501/125C12N2501/145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,139
App. No.
17/641,699
Granted
Jul 7, 2026
Kind
B2
Abstract

The present invention discloses a composition of an albumin-free, serum-free medium suited for culturing human hematopoietic stem cells and an albumin-free culturing method. According to the present invention, a method of culturing human hematopoietic stem cells is provided which comprises bringing human hematopoietic stem cells into contact with PVA and a PI3K activator.

Claims (26)

1 . A method of culturing or manufacturing human hematopoietic stem cells,

the method comprising culturing human hematopoietic stem cells in a culture medium,

the culture medium comprising polyvinyl alcohol,

(1) comprising a phosphatidylinositol 3-kinase (PI3K) activator and one or more selected from the group consisting of thrombopoietin (TPO) and a TPO receptor agonist;

(2) comprising one or more selected from the group consisting of a stem cell factor (SCF) and a PI3K activator, and a TPO receptor agonist; or

(3) comprising a PI3K activator and a TPO receptor agonist,

wherein the PI3K activator is 740Y-P,

wherein the TPO receptor agonist is butyzamide, and

wherein the number of human hematopoietic stem cells is increased by the culturing.

2 . The method of claim 1 , wherein the culture medium is a serum-free medium or chemically defined medium.

3 . The method of claim 1 , wherein the culture medium comprises substantially no albumin.

4 . The method of claim 1 , which comprises obtaining an increased amount of human hematopoietic stem cells.

5 . The method of claim 1 , wherein the culture medium does not comprise SCF.

6 . The method according to claim 1 , wherein the culture medium comprises 740Y-P and butyzamide.

7 . The method of claim 1 , wherein the culture medium comprises neither SCF nor TPO.

8 . The method of claim 1 , wherein the culture medium further comprises 4-N-[2-benzyl-7-(2-methyltetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl]cyclohexane-1,4-diamine (UM171).

9 . The method of claim 8 , wherein the duration of culture is 7 days or longer.

10 . The method of claim 1 , wherein the culture medium is a chemically defined medium.

11 . The method of claim 1 , wherein the culture medium is substantially free from albumin or cytokines.

12 . A method of culturing or manufacturing human hematopoietic stem cells, the method comprising culturing human hematopoietic stem cells in a culture medium comprising polyvinyl alcohol as an albumin replacement,

(1) a PI3K activator and one or more selected from the group consisting of TPO and a TPO receptor agonist;

(2) one or more selected from the group consisting of SCF and a PI3K activator, and a TPO receptor agonist; or

(3) a PI3K activator and a TPO receptor agonist,

wherein the PI3K activator is 740Y-P, and

wherein the TPO receptor agonist is butyzamide.

13 . The method of claim 12 , which further comprises 4-N-[2-benzyl-7-(2-methyltetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl]cyclohexane-1,4-diamine (UM171).